A novel fusion variant of the MORF and CBP genes detected in therapy-related myelodysplastic syndrome with t(10;16)(q22;p13)

Br J Haematol. 2003 Jan;120(2):271-3. doi: 10.1046/j.1365-2141.2003.04059.x.

Abstract

We report a case of therapy-related myelodysplastic syndrome (t-MDS) with t(10;16)(q22;p13), in which novel fusion transcripts of the MORF and CBP genes were detected. In one MORF-CBP fusion transcript, exon 15 of the MORF gene was fused in frame with exon 5 of the CBP gene. In a reciprocal CBP-MORF transcript, exon 4 of the CBP gene was fused in frame with exon 16 of the MORF gene. This is the first reported case of t-MDS associated with t(10;16), and provides molecular evidence that the novel MORF-CBP and/or CBP-MORF fusion protein(s) might play an important role in the development of t-MDS.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetyltransferases / genetics*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carrier Proteins / genetics*
  • Chromosomes, Human, Pair 10
  • Chromosomes, Human, Pair 16
  • Cytarabine / administration & dosage
  • Female
  • Gene Rearrangement
  • Histone Acetyltransferases
  • Humans
  • Idarubicin / administration & dosage
  • Leukemia, Myeloid, Acute / drug therapy
  • Middle Aged
  • Myelodysplastic Syndromes / chemically induced
  • Myelodysplastic Syndromes / genetics*
  • Reverse Transcriptase Polymerase Chain Reaction
  • Saccharomyces cerevisiae Proteins / genetics*
  • Sequence Analysis, DNA
  • Translocation, Genetic*

Substances

  • Carrier Proteins
  • Saccharomyces cerevisiae Proteins
  • citrate-binding transport protein
  • Cytarabine
  • Acetyltransferases
  • Histone Acetyltransferases
  • Idarubicin